Navigation Links
Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
Date:8/26/2009

DURHAM, N.C., Aug. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company will present at investor conferences in New York on Sept. 9 and Zurich on Sept. 10, 2009.

Kirk Harrington, senior vice president, Warfighter Division and Government Affairs, will present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 9, 2009 at 2:00 p.m. eastern time.

A live, audio webcast of Harrington's presentation will be available through the Investor Relations section of the Oxygen Biotherapeutics, Inc. website. A replay will be available following the event. Webcast login information will be provided on the company website prior to the presentation.

The following day, the company chairman and CEO, Chris Stern, will present at an investor conference in Zurich. The presentation will be at the Dolder Grand Hotel and is scheduled for 5:00 p.m. in the Garden Salon. The Zurich presentation will not be webcast but will be open to interested investors.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
7. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
10. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
11. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patient ... developed with Wi-Fi connectivity to reduce the amount of wiring in a healthcare ... addition, compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, ...
(Date:5/23/2017)... ... 2017 , ... Firmex today announced the general ... for organizations to send and gather large files and confidential documents beyond the ... size limitations. , Using the same market-tested infrastructure as Firmex’s flagship Virtual ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... source of human cardiovascular cells for research and the development of cardiac ... possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked as ... Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who ... perform against those strategies. NetDimensions’ ranking as a Leader due to its strengths ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):